Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Questionnaire for biotechs: Vical incorporated.

Igor P Bilinsky1, Larry R Smith

  • 1a Igor Bilinsky is the Senior Vice President, Corporate Development, and Larry Smith is the Vice President, Vaccine Research of Vical Incorporated.

Human Vaccines & Immunotherapeutics
|December 4, 2014
PubMed
Summary

This company

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients.

EClinicalMedicine·2021
Same author

Pharmacokinetics and Immunogenicity of ASP0113 in CMV-Seronegative Dialysis Patients and CMV-Seronegative and -Seropositive Healthy Subjects.

Clinical pharmacology in drug development·2020
Same author

First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy Adults.

Antimicrobial agents and chemotherapy·2019
Same author

The Siderophore Transporter Sit1 Determines Susceptibility to the Antifungal VL-2397.

Antimicrobial agents and chemotherapy·2019
Same author

Population Pharmacokinetic Modeling of VL-2397, a Novel Systemic Antifungal Agent: Analysis of a Single- and Multiple-Ascending-Dose Study in Healthy Subjects.

Antimicrobial agents and chemotherapy·2019
Same author

A cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.

Vaccine·2015

Area of Science:

  • Biotechnology and Pharmaceutical Development
  • Clinical Trials and Regulatory Affairs
  • Biopharmaceutical Risk Assessment

Background:

  • The company's strategic focus involves multiple product candidates.
  • Collaborative partnerships are integral to the company's development pipeline.
  • The developmental status of product candidates is subject to ongoing evaluation.

Discussion:

  • Clinical trial success is not guaranteed.
  • Regulatory approval pathways present challenges.

Key Insights:

  • Product candidate safety and efficacy are under investigation.
  • Timelines for clinical trials and market approval are uncertain.

Outlook:

  • Future results depend on successful clinical trials and regulatory approvals.
  • Company performance is linked to collaborative partnerships.

Related Experiment Videos